Malone CF, Stegmaier K. Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma. Cancer Cell. 2017;32(3):271-273. doi:10.1016/j.ccell.2017.08.011
LaRochelle JR, Fodor M, Ellegast JM, et al. Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. Bioorg Med Chem. 2017;25(24):6479-6485. doi:10.1016/j.bmc.2017.10.025
Lupberger J, Croonenborghs T, Suarez AAR, et al. Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of Hepatitis C Virus-Infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology. 2019;157(2):537-551.e9. doi:10.1053/j.gastro.2019.04.003
Ellis L, Loda M. LSD1: A single target to combat lineage plasticity in lethal prostate cancer. Proc Natl Acad Sci U S A. 2018;115(18):4530-4531. doi:10.1073/pnas.1804205115
Jayson CBK, Arlt H, Fischer AW, Lai ZW, Farese RV, Walther TC. Rab18 is not necessary for lipid droplet biogenesis or turnover in human mammary carcinoma cells. Mol Biol Cell. 2018;29(17):2045-2054. doi:10.1091/mbc.E18-05-0282
Raj L, Ide T, Gurkar AU, et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature. 2011;475(7355):231-4. doi:10.1038/nature10167
Keckesova Z, Donaher JL, De Cock J, et al. LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature. 2017;543(7647):681-686. doi:10.1038/nature21408
Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-1623. doi:10.1038/ng.3958
Janouskova H, Tekle GE, Bellini E, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046-1054. doi:10.1038/nm.4372
Sandoval GJ, Pulice JL, Pakula H, et al. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Mol Cell. 2018;71(4):554-566.e7. doi:10.1016/j.molcel.2018.06.040